Clinical Trial Update: Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

View source ↗

Summary

This completed clinical trial update discusses cardiovascular morbidity observed during treatment of overactive bladder with beta-3 adrenergic agonists, highlig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Karolinska Institutet | Conditions: Overactive Bladder | Status: COMPLETED